Berlin-based x-cardiac announces certification of its innovative digital biomarker platform under the Medical Device Regulation, aimed at improving patient care and safety in critical medical settings.
Berlin’s x-cardiac Achieves Milestone Certification for Digital Biomarker Platform Under MDR
Berlin, Germany – Berlin-headquartered medical technology firm x-cardiac has announced the successful certification of its pioneering x-cardiac-platform under the stringent Medical Device Regulation (MDR). This certification heralds a significant milestone for x-cardiac as it introduces a revolutionary generation of products aimed at enhancing patient care and bolstering safety measures in critical medical situations.
The x-cardiac-platform is an advanced digital biomarker tool specifically engineered to improve patient safety and treatment efficacy, especially in critical care environments. Achieving MDR certification signifies that the platform adheres to the highest European standards for safety and performance, reflecting robust regulatory compliance.
This new product series includes two notable plug-ins: x-c-bleeding and x-c-renal-injury. These innovative additions play a crucial role in the early detection and management of bleeding and kidney injuries post-major heart surgeries. This technology leverages cutting-edge algorithms to predict and mitigate postoperative complications, potentially transforming clinical outcomes.
Oliver Höppner, CEO of x-cardiac, expressed his enthusiasm about the potential impact of the new product line. “With the launch of our new platform, we can offer advanced solutions for predicting and managing postoperative complications in everyday clinical practice. Furthermore, we aim to extend our market reach beyond Germany, Austria, and Switzerland through strategic collaborations with sales partners,” Höppner stated. He also mentioned that x-cardiac plans to present these ground-breaking products at the EACTS Annual Summit 2024 in Lisbon, which will provide a platform for showcasing their innovations to a community of cardiac surgery professionals.
The company’s Chief Medical Officer, Prof. Dr. Alexander Meyer, emphasised the unique capabilities of the x-cardiac-platform, noting, “Our platform sets a new benchmark in patient care by performing local validation of algorithms for each customer. This ensures our solutions are adapted to the specific needs and contexts of individual users, with optional fine-tuning for enhanced precision.”
The upcoming EACTS Annual Summit 2024 in Lisbon is scheduled to be a significant event for x-cardiac, offering an opportunity to demonstrate their advancements to a specialised audience of healthcare practitioners and stakeholders.
For additional information, interested parties can contact Oliver Höppner from x-cardiac GmbH at [email protected] or visit the company’s website at www.xcardiac.com.
This information was circulated by Pressat, a press release distribution service, on Wednesday 2 October 2024.
Source: Noah Wire Services
